Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer

Pedersen, Ann Christina; Sørensen, Patricia Diana; Jacobsen, E. H.; Madsen, Jonna Skov; Brandslund, Ivan

doi:10.1515/cclm-2012-0488

Cited by 53 publications

(40 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent studies demonstrated that serial determination of CA 15-3 and CEA levels during the postoperative follow-up of breast cancer patients may be useful for early detection of preclinical recurrence or metastatic disease (8,9). In addition, the serum levels of CA 15-3 and CEA may be used to predict response to chemotherapy in patients with metastatic breast cancer (MBC) (10).…”

Section: Introductionmentioning

confidence: 99%

Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer

Geng

Liang

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The objective of this study was to investigate the association of serum cancer antigen and carcinoembryonic antigen (CEA) levels with clinicopathological parameters in patients diagnosed with metastatic breast cancer (MBC). We retrospectively evaluated the medical records of 284 patients diagnosed with MBC between January, 2007 and December, 2012 who fulfilled the specified criteria and the association between the levels of the two tumor marker and clinicopathological parameters was analyzed. Of the 284 patients, elevated CA 15-3 and CEA levels at initial diagnosis of recurrence were identified in 163 (57.4%) and 97 (34.2%) patients, respectively. Elevated CA 15-3 and CEA levels were significantly associated with breast cancer molecular subtypes (P<0.001 and P=0.032, respectively). Cases with luminal subtypes exhibited a higher percentage of elevated CA 15-3 and CEA levels compared to non-luminal subtypes. Elevated CA 15-3 level was correlated with bone metastasis (P=0.017). However, elevation of CEA was observed regardless of the site of metastasis. Elevation of CA 15-3 was significantly more common in MBC with multiple metastatic sites compared to MBC with a single metastasis (P=0.001). However, the incidence of elevated CEA levels did not differ between patients with a single and those with multiple metastatic sites. In conclusion, elevated CA 15-3 and CEA levels at initial diagnosis of recurrence were found to be associated with breast cancer molecular subtypes, whereas an elevated CA 15-3 level was significantly correlated with bone metastasis and an elevated CEA level was observed regardless of metastatic site. The proportion of MBC cases with elevated CA 15-3 levels differed according to the number of metastatic sites.

show abstract

Section: Introductionmentioning

confidence: 99%

Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer

Geng

Liang

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Additionally, our data indicate that determining the serum concentrations of CEA and CA15-3 provides a simple yet robust method to predict a patient's therapeutic response. However, since our results are based on a retrospective analysis, other tumor markers such as HER-2, epidermal growth factor receptor or tissue polypeptide antigen (25,(39)(40)(41) were not included in our analysis. Analyzing these markers in addition to CEA and CA15-3 could potentially provide even more accurate predictions of therapeutic response than those reported in the present study.…”

mentioning

confidence: 99%

Elevation of serum CEA and CA15‑3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients

Yang

Zhang

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. The aim of the present study was to assess the correlation between therapeutic response and carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA15-3) levels in advanced breast cancer patients with non-assessable lesions or stable disease (SD) according to the Response Evaluation Criteria in Solid Tumors. A total of 232 female patients with recurrent tumors following radical mastectomy were recruited, including 76 patients with non-assessable lesions and 60 patients with SD. The correlation between CEA and CA15-3 changes, progression-free survival (PFS) and therapeutic response were analyzed in the non-assessable and SD patient groups. For all subjects, the association between the patients' serum tumor markers levels and the clinical presentation of the tumor, as well as the correlation between initial tumor marker levels and PFS, were analyzed. An increase in CEA (an increment of >2 ng/ml) or CA15-3 levels (an increase of >15 U/ml) following the second cycle of treatment correlated with shorter PFS in both non-assessable and SD patients, and with poor clinical outcome in SD patients. High CA15-3 levels correlated with hormone receptor-positive tumors, multiple metastases and liver metastases. Bone metastases correlated with high levels of both CEA and CA15-3. Relatively low CEA and CA15-3 concentrations were associated with triple-negative and locally invasive tumors. High CEA and CA15-3 levels at the beginning of relapse correlated with shorter PFS. The present study illustrates that CEA and CA15-3 levels correlate with several factors in recurrent breast cancer patients. Elevated levels of CEA and CA15-3 at the beginning of relapse may predict shorter PFS. Furthermore, elevation of CEA and CA15-3 levels following the second therapeutic cycle predict poor therapeutic response in patients with non-assessable lesions and SD. Our findings suggest that alterations in CEA and CA15-3 levels can predict therapeutic response in advanced breast cancer patients.

show abstract

“…HER-2 is not only an important therapeutic target in breast cancer, but as reported by Pedersen et al [ 7 ] high circulating concentrations of this protein may indicate the presence of distant metastases. Moreover, circulating HER-2 may also be used to assess the response to treatment.…”

mentioning

confidence: 83%

“…Distant metastases are in most cases incurable, and early diagnosis of metastatic disease may numerically improve the prognosis only as a result of the leadtime bias. From a practical point of view the only curable recurrence is the local recurrence, but as also shown in the report by Pedersen et al [ 7 ] increased concentrations of tumor biomarkers are rare in patients with isolated local recurrence. Thus, many clinicians see serial determination of tumor biomarkers as being of little help in the practical management of the patient with breast cancer.…”

mentioning

confidence: 87%

“…Pedersen et al describe a retrospective experience with three circulating tumor biomarkers, the glycoprotein CA15-3, carcinoembryonic antigen (CEA) and human epidermal growth factor receptor (HER)-2 in the detection of recurrent disease in patients with breast cancer [ 7 ]. This study clearly demonstrates the limitations of tumor biomarkers to detect recurrence in this tumor.…”

mentioning

confidence: 87%

See 1 more Smart Citation

Biomarkers in the treatment of cancer: opportunities and pitfalls

Melichar

2013

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer

Abstract: The combination of several tumour markers enhances the sensitivity for detection of metastatic breast cancer. We recommend HER2 or the combination of CEA and HER2 in tissue HER2+ and CA 15-3 or the combination of CA 15-3 and CEA in tissue HER2-.

Cited by 53 publications

References 23 publications

Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer

Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer

Elevation of serum CEA and CA15‑3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients

Biomarkers in the treatment of cancer: opportunities and pitfalls

Contact Info

Product

Resources

About